Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by Yonsei University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Yonsei University
ClinicalTrials.gov Identifier:
NCT00773123
First received: October 15, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
  Purpose

RT-View utilizes spectral domain technology to assess both RNFL and ganglion cell layer thickness. This study aims to correlate visual field defects in patients with glaucoma to both RNFL and ganglion cell layer thickness.


Condition
Primary Open Angle Glaucoma

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Yonsei University:

Primary Outcome Measures:
  • Ganglion cell layer thickness [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Visual field defect [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: October 2008
Estimated Study Completion Date: December 2008
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Primary open angle glaucoma
2
Normal controls

  Eligibility

Ages Eligible for Study:   10 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

primary open angle glaucoma

Criteria

Exclusion Criteria:

  • Evidence of retinal disease
  • Neovascular glaucoma
  • Secondary glaucoma due to intraocular inflammation
  • Lens induced glaucoma
  • Tumor induced glaucoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00773123

Contacts
Contact: Chan Yun Kim, MD,PhD 82-2-2228-3570 kangeye@hotmail.com
Contact: Sung Yong Kang, MD 82-2-2228-3570 kangeye@yuhs.ac

Locations
Korea, Republic of
Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University School of Medicine Recruiting
Seoul, Korea, Republic of, 120-752
Contact: Chan Yun Kim, MD,PhD    82-2-2228-3570    kangeye@hotmail.com   
Contact: Sung Yong Kang, MD    82-2-2228-3570    kangeye@yuhs.ac   
Principal Investigator: Chan Yun Kim, MD,PhD.         
Sponsors and Collaborators
Yonsei University
  More Information

No publications provided

Responsible Party: Kim,Chan Yun, Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University School of Medicine
ClinicalTrials.gov Identifier: NCT00773123     History of Changes
Other Study ID Numbers: 08-0342
Study First Received: October 15, 2008
Last Updated: October 15, 2008
Health Authority: Korea: Food and Drug Administration

Keywords provided by Yonsei University:
RT-View
Spectral domain OCT
Ganglion cell layer
RNFL
Visual field defect

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Eye Diseases
Ocular Hypertension

ClinicalTrials.gov processed this record on October 23, 2014